Here is a fact about the pharmaceutical industry that does not get put on billboards: most drug candidates fail, and a good number of them fail for boring reasons. They were safe. They were manufacturable. They cleared the early trials. They just didn't beat placebo in the one disease the sponsor happened to be testing them against - so they got shelved, written down, and filed in a folder nobody opens. The molecule was fine. The indication was wrong. This is an enormous amount of value to leave in a filing cabinet, and roughly since 2005 a company in Exton, Pennsylvania has been in the business of pointing that out.
The company is Melior Discovery, and its core insight is almost aggressively common-sense. If a drug doesn't work for the disease you tested it against, the correct next question is not "throw it away" but "what does it work for?" The problem, historically, is that answering that question was slow and expensive. You'd have to guess a new indication, build a study, run it, and repeat - one disease at a time, one guess at a time. Nobody was going to do that for a compound they'd already given up on. The math didn't work.
"Capture the untapped value of therapeutics." It is a slogan, but it is also a fairly literal description of the business.
The multiplexing trick
Melior's answer is a platform called theraTRACE, and the thing that makes it interesting is a word borrowed from telecommunications: multiplexing. Instead of testing a compound against one disease model at a time, theraTRACE runs it through a large, integrated panel of validated in vivo models more or less simultaneously, reading many disease-relevant signals at once. The company's own phrasing is that the approach "systematically and rapidly" identifies "previously unknown applications" for a compound, using less time, less test material, and fewer test subjects than the one-at-a-time approach it replaces.
That efficiency is the whole ballgame. If screening a shelved molecule across dozens of indications is cheap enough, then suddenly it's worth doing - and the drug graveyard turns from a sunk cost into an inventory of leads. Melior has built and validated a library that started at 80-plus animal models and now runs past 150 rat and mouse models across roughly 14 therapeutic areas, from metabolic disease and oncology to neurology, pain, and inflammation.
The company was co-founded by Andrew Reaume and Michael Saporito. Reaume's origin story is the kind pharma likes to tell: he was a senior business analyst at Pfizer, in genomics and proteomics, when he came up with the idea of a platform for systematically phenotyping genetically modified mice. He built a version of it inside Pfizer with an outside collaborator, then left to build the real thing himself. It is, in a small way, the classic corporate-refugee arc - the idea that was too sideways for the big company becomes the whole company somewhere else.
The trick that pays: MLR-1023
The proof that any of this works is MLR-1023, and it is a genuinely good example. It is an oral insulin sensitizer for type 2 diabetes, and notably it is the first such drug that does not work through PPAR-gamma - the pathway most existing insulin sensitizers use. In preclinical work it lowered blood glucose without the hypoglycemia or weight gain that dog other diabetes drugs. This is exactly the kind of thing Melior's platform is supposed to surface: an old molecule with a genuinely new and useful behavior. Melior licensed it to Korea's Bukwang Pharmaceutical in 2013, spun it into a separate company, and pushed it through two Phase 2 studies involving some 600 subjects across 80 clinical sites in two countries.
A drug that traces back to an old compound becomes a novel, non-PPAR-gamma diabetes candidate. That is the pitch, made real.
Two businesses in one building
What makes Melior a little unusual is that it refuses to pick a lane. Most companies decide whether they are a service business or a product business. Melior is both. On one side it is a contract research organization - a fee-for-service preclinical lab that sells its in vivo pharmacology and theraTRACE screening to other drug companies. On the other side, when the platform turns up a molecule worth developing, Melior develops it, through wholly separate spinouts - Melior Pharmaceuticals I and II - and out-licenses the result. The service business funds and de-risks the product business; the product business proves the service business works.
That model has attracted an unusually large roster of partners for a company of two dozen people. Melior has publicly disclosed research relationships built on its repositioning technology with Pfizer, Merck, Johnson & Johnson, and AstraZeneca, and more recently generated brain-tumor models for the biotech Modifi Bio - replicating and expanding the partner's own data well enough, the company says, to help those results hold up in front of investors. Across the Melior companies, Reaume has been credited with raising roughly $15 million in capital and closing something like $40 million in partnering deals.
The recognition has followed. Pharma Tech Outlook named Melior a top-20 CRO in 2023; in 2024 Life Sciences Review went further and named it CRO of the Year, singling out theraTRACE along with its oncology-focused cousin immuno-theraTRACE and an analgesic-focused version, opioidTRACE. The lab is AAALAC International accredited, DEA licensed across Schedules I-V, and - a detail that says something about how the place is run - certified as a Great Place to Work. None of this is flashy. It is, appropriately for a company whose product is rigor, mostly a story about doing careful work and building a reputation one replicated result at a time.